JP2005502722A5 - - Google Patents

Download PDF

Info

Publication number
JP2005502722A5
JP2005502722A5 JP2003528495A JP2003528495A JP2005502722A5 JP 2005502722 A5 JP2005502722 A5 JP 2005502722A5 JP 2003528495 A JP2003528495 A JP 2003528495A JP 2003528495 A JP2003528495 A JP 2003528495A JP 2005502722 A5 JP2005502722 A5 JP 2005502722A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
phenyl
substituted
furyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003528495A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005502722A (ja
Filing date
Publication date
Priority claimed from US10/242,826 external-priority patent/US7049334B2/en
Application filed filed Critical
Publication of JP2005502722A publication Critical patent/JP2005502722A/ja
Publication of JP2005502722A5 publication Critical patent/JP2005502722A5/ja
Pending legal-status Critical Current

Links

JP2003528495A 2001-09-14 2002-09-16 学習及び記憶の亢進ならびに健忘症の治療 Pending JP2005502722A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32238901P 2001-09-14 2001-09-14
US10/242,826 US7049334B2 (en) 2001-09-14 2002-09-13 Enhancement of learning and memory and treatment of amnesia
PCT/US2002/029294 WO2003024397A2 (en) 2001-09-14 2002-09-16 Enhancement of learning and memory and treatment of amnesia

Publications (2)

Publication Number Publication Date
JP2005502722A JP2005502722A (ja) 2005-01-27
JP2005502722A5 true JP2005502722A5 (enExample) 2006-01-05

Family

ID=26935379

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003528495A Pending JP2005502722A (ja) 2001-09-14 2002-09-16 学習及び記憶の亢進ならびに健忘症の治療

Country Status (10)

Country Link
US (1) US7049334B2 (enExample)
EP (1) EP1425011B1 (enExample)
JP (1) JP2005502722A (enExample)
KR (1) KR100889515B1 (enExample)
AT (1) ATE447405T1 (enExample)
AU (1) AU2002327635B2 (enExample)
CA (1) CA2460005C (enExample)
DE (1) DE60234263D1 (enExample)
NZ (1) NZ532022A (enExample)
WO (1) WO2003024397A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077702A1 (en) * 2001-09-14 2004-04-22 Wen-Mei Fu Treatment of nuerodegenerative diseases
JP4499721B2 (ja) 2003-06-30 2010-07-07 ヒフ バイオ,インク. 化合物、組成物および方法
JP2005089457A (ja) * 2003-09-03 2005-04-07 Yung Shin Pharmaceutical Industry Co Ltd 骨成長を促進するまたは骨吸収を阻害するための薬剤組成物
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
AU2007276763B2 (en) * 2006-07-24 2011-03-17 University Of Maryland, Baltimore Heme oxygenase inhibitors and methods of therapeutic use
WO2008070579A2 (en) * 2006-12-01 2008-06-12 Loma Linda University Medical Center Inhibition of brain enzymes involved in cerebral amyloid angiopathy and macular degeneration

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5240947A (en) * 1992-11-30 1993-08-31 National Science Council 2,3,4,5-substituted furo[2,3-c]pyrazole derivatives
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 1−(置換ベンジル)−3−(置換アリール)縮合ピラゾール類、その製造法及びその用途
US7115661B1 (en) * 1999-12-29 2006-10-03 Queen's University At Kingston Methods and compositions for mitigating pain
DE19642255A1 (de) * 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
DE19744026A1 (de) * 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
GB9920566D0 (en) * 1999-08-31 1999-11-03 Univ London Screen for axon viability
WO2001054680A2 (en) * 2000-01-26 2001-08-02 Cedars-Sinai Medical Center Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor
AR031176A1 (es) * 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina

Similar Documents

Publication Publication Date Title
JP2004516314A5 (enExample)
JP2005523922A5 (enExample)
JP2008510828A5 (enExample)
CY1110986T1 (el) Αζολια ως αναστολεις της αποκαρβοξυλασης μηλονυλο-συνενζυμου α χρησιμα ως μεταβολικοι διαμορφωτες
JP2010511721A5 (enExample)
JP2009536221A5 (enExample)
NO20072515L (no) 2-amido-4-fenyltnazolderivater, fremstilling og terapeutsik anvendelse derav
EA201100129A1 (ru) Композиции и способы применения модулятора рецептора 5ht-2c
JP2004518723A5 (enExample)
JP2007508359A5 (enExample)
ATE471323T1 (de) Purinderivate als antagonisten an purinergen rezeptoren
CY1111951T1 (el) Φαινυλο-καρβοξαμιδικες ενωσεις χρησιμες για την αντιμετωπιση πονου
JP2007508362A5 (enExample)
EA200401114A3 (ru) Замещённые гидроксиэтиламины
DE60333746D1 (de) Thienylverbindungen
JP2010520214A5 (enExample)
JP2004502755A5 (enExample)
JP2007519618A5 (enExample)
EA200501703A1 (ru) Применение производных азетидинкарбоксамида в терапии
UY27979A1 (es) Indoles sustituidos en posición 2,4
JP2010535706A5 (enExample)
JP2005502722A5 (enExample)
JP2004521150A5 (enExample)
JP2006510659A5 (enExample)
JP2005075834A5 (enExample)